VIVS VIVOSIM LAB

-

VIVOSIM LAB Reported Earnings

Wednesday, August 12, 2026 · 12:00 AM ET

VIVOSIM LAB (VIVS) reported a loss of $0.25 per share on revenue of $0.02 million for the . . Revenue fell 51.35% compared to the same quarter a year ago.

VivoSim Labs Inc. is a clinical-stage biotechnology company. It involved in developing drugs which are demonstrated to be effective in three-dimensional human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease. VivoSim Labs Inc., formerly known as Organovo Holdings Inc., is based in SAN DIEGO, United States.

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.25)
Earnings Whisper®
Consensus Estimate
Earnings Surprise
Earnings Growth78.1 %
Reported Revenue
$0.02M
Revenue Estimate
Revenue Surprise
Revenue Growth-51.4 %